vTv Therapeutics Inc.VTVT

vTv Therapeutics Inc. Stock Compensation Disclosure

10-KFiled Mar 10, 20262 min read
Share-Based Compensation
The Company has issued non-qualified stock option awards to management, other key employees, consultants, and nonemployee directors and these options vest ratably over a four-year period. In addition, we issued options in connection with the private placement on February 27, 2024, that vest ratably over a three-year period. The option awards expire after a term of ten years from the date of grant. For the years ended December 31, 2025, 2024 and 2023, the Company recognized $3.8 million, $2.8 million and $1.6 million, respectively, of compensation expense related to share-based awards. Given that the Company has established a full valuation allowance against its deferred tax assets, the Company has recognized no tax benefit related to these awards. As of December 31, 2025, the Company had total unrecognized stock-based compensation expense of approximately $6.2 million, which is expected to be recognized on a straight-line basis over a weighted average period of 2.5 years. The weighted average grant date fair value for all option grants during the years ended December 31, 2025, 2024 and 2023 was $15.37, $14.76 and $24.78 per option, respectively. The total intrinsic value of stock options exercised was $0.2 million during the year ended December 31, 2025. The total fair value of stock options vested during the years ended December 31, 2025, 2024 and 2023 was $2.9 million, $2.9 million and $2.2 million, respectively.
The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions during the years ended December 31, 2025, 2024 and 2023:
For the Year Ended December 31,
202520242023
Expected volatility
89.03% - 93.76%
96.84% - 108.61%
121.01% - 126.76%
Expected life of option, in years
5.5 - 6.1
5.5 - 6.1
5.5 - 6.1
Risk-free interest rate
3.68% - 4.13%
3.44% - 4.36%
3.42% - 4.61%
Expected dividend yield0.00%0.00%0.00%
The following table summarizes the activity related to the stock option awards for the year ended December 31, 2025 (in thousands, except per share amounts):
Number of SharesWeighted
Average Exercise Price		Aggregate Intrinsic Value (in thousands)
Awards outstanding at December 31, 2024705,593$35.85 
Granted409,06620.14 
Exercised(21,355)11.81 
Forfeited(58,350)16.98 
Expired(17,334)384.72 
Awards outstanding at December 31, 20251,017,620$25.18 $19,750 
Options exercisable at December 31, 2025404,640$35.25 $6,593 
Weighted average remaining contractual term6.9 Years
Options vested and expected to vest at December 31, 2025899,743$26.00 
Weighted average remaining contractual term8.0 Years 
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
202520242023
Research and development$1,124 $742 $425 
General and administrative2,651 2,015 1,153 
Total share-based compensation expense$3,775 $2,757 $1,578 
Free Sentinel

Want the next vTv Therapeutics Inc. stock compensation disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment vTv Therapeutics Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Mar 10, 2026Showing above
2024Mar 20, 2025
2023Mar 13, 2024
2022Mar 6, 2023
2021Mar 29, 2022
2020Feb 24, 2021
2019Feb 21, 2020
2018Feb 26, 2019
2017Feb 27, 2018
2016Feb 24, 2017
2015Mar 4, 2016

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&ELeasesSegmentsDebtCommitmentsNew StandardsPay vs Performance